Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S (NASDAQ: EVAX) is a clinical-stage TechBio company that regularly issues news on its AI-Immunology™ powered vaccine and immunotherapy programs. The company’s updates highlight progress across cancer, infectious disease and autoimmune disease research, making EVAX news relevant for investors and followers of AI-driven biotechnology.
News from Evaxion often covers clinical and preclinical data from its oncology pipeline, including the personalized cancer vaccine EVX-01 for advanced melanoma and the ERV-based off-the-shelf cancer vaccine candidate EVX-04 for acute myeloid leukemia. Releases may detail biomarker findings, immune response data, and presentations at major scientific meetings such as oncology and hematology conferences.
On the infectious disease side, Evaxion publishes updates on vaccine candidates like the gonorrhea program EVX-B2 and the CMV vaccine program EVX-V1. These announcements can include preclinical efficacy data, discovery of novel AI-identified antigens, and progress in optimizing vaccine components such as AI-optimized glycoprotein antigens. Business development news may also describe option decisions, out-licensing arrangements and partnership discussions with pharmaceutical companies.
Corporate and financial communications form another important part of the EVAX news flow. Evaxion reports business updates, financial results, capital raises, changes to its Articles of Association related to share capital, and its financial calendar through press releases and accompanying SEC Form 6-K filings. The company also issues announcements about strategic milestones, such as expanding AI-Immunology™ into autoimmune diseases or enhancing the platform with automated vaccine design modules.
This news page aggregates these items so readers can follow Evaxion’s scientific progress, platform evolution, partnership activity and corporate developments in one place. For those tracking AI-based drug discovery, cancer vaccines and infectious disease vaccines, the EVAX news feed provides ongoing insight into how Evaxion applies its AI-Immunology™ platform across multiple therapeutic areas.
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company, will present preclinical Proof-of-Concept for its precision cancer vaccine concept at the ESMO Immuno-Oncology Congress from December 11-13, 2024, in Geneva, Switzerland.
The data, derived from studies in human cells and mouse tumor models, highlight human T-cell responses and mouse tumor growth inhibition induced by the precision ERV (endogenous retrovirus) vaccine targets identified using Evaxion's AI-Immunology™ platform.
ERV antigens can be selected for precision therapeutic cancer vaccines, offering new treatments for various cancer types, including those unresponsive to conventional immunotherapy. This approach allows for designing vaccines effective across diverse immune system characteristics, suitable for a wide range of patients.
Evaxion will use this preclinically validated concept to design new precision vaccine candidates to enhance its existing pipeline.
Conference Details:
Abstract title: AI-designed cancer vaccines: antigens from the dark genome are promising cancer vaccine targets
Poster#: 124P
Location: Foyer Mezzanine
Date/Time: December 12, 2024, at 12.30 CET/06.30 EST
Presenter: Daniela Kleine-Kohlbrecher, Senior Project Manager at Evaxion
Evaxion Biotech (NASDAQ: EVAX) has received a delisting determination from Nasdaq due to failure to maintain stockholders' equity of at least $2.5 million. The company has appealed the decision and requested a hearing, seeking another 180-day extension to comply with Nasdaq's equity requirements. The appeal will suspend any trading suspension until the hearing process concludes. This follows a previous deficiency letter received on May 7, 2024, after which Evaxion was granted a 180-day extension that expired on November 4, 2024. The company plans to increase stockholder's equity through business development income and capital markets activities, though compliance cannot be guaranteed.
Evaxion reported positive preclinical data for its cytomegalovirus (CMV) vaccine program EVX-V1. The study demonstrated that CMV antigens identified using their proprietary AI-Immunology™ platform successfully triggered targeted immune responses. The results also validated their proprietary prefusion glycoprotein B (gB) antigen design, showing virus neutralization capabilities. Based on these findings, Evaxion is proceeding with the development of a multi-component CMV vaccine candidate.
Evaxion Biotech (NASDAQ: EVAX) announced Q3 2024 financial results and business updates. Key highlights include an expanded collaboration with MSD, positive phase 2 data for EVX-01 cancer vaccine showing 69% Overall Response Rate, and preclinical Proof-of-Concept for EVX-B2 mRNA Gonorrhea vaccine. Q3 revenue was $3.0 million compared to nil in Q3 2023. Net loss decreased to $1.9 million ($0.04 per share) from $5.7 million ($0.21 per share) year-over-year. Cash position was $4.6 million as of September 30, 2024, with runway into March 2025. The company faces Nasdaq compliance issues regarding minimum stockholder's equity requirements.
Evaxion Biotech (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has scheduled its Q3 2024 financial results announcement and business update for October 31, 2024, before Nasdaq CM opening. The company's Executive Management will host a conference call and webcast at 13:30 CET/08:30 EST on the same day. The event is free and open to the public, with advance registration required for participation. A webcast recording will be made available on the company's website after the event.
Evaxion Biotech A/S (NASDAQ: EVAX) has reported strong validation of its AI-Immunology™ platform in multiple clinical trials. The company, specializing in AI-powered vaccine development, has gathered evidence from three separate clinical trials demonstrating the platform's ability to select clinically relevant vaccine targets.
Key findings include:
- Statistically significant correlation between AI-Immunology™ prediction scores and immunological responses in patients
- Strongest outcomes generated by top-ranked AI-Immunology™ vaccine targets
- In one trial, a statistically significant correlation between AI-Immunology™ prediction scores and Progression Free Survival (PFS)
The data supports the platform's potential in selecting effective vaccine targets and allows for continuous refinement of AI-Immunology™, broadening its commercial potential. Evaxion's CEO, Christian Kanstrup, emphasized the importance of generating relevant clinical data for the ongoing development of the platform.
Evaxion Biotech A/S (NASDAQ: EVAX) has reported significant improvements in its AI-Immunology™ platform's predictive power for clinically relevant vaccine targets. In the ongoing phase 2 trial of their personalized cancer vaccine EVX-01, 79% of the AI-predicted vaccine targets triggered a tumor-specific immune response, up from 58% in the phase 1 trial.
This improvement is attributed to iterative learning and integration of advanced bioinformatics and machine learning techniques. The company believes this enhanced precision boosts the potential of its AI-derived vaccine candidates and is important for clinical efficacy and commercial potential.
CEO Christian Kanstrup emphasized the importance of this progress, stating that the 79% response rate compares favorably to other personalized cancer neoantigen trials. He also noted that the strong clinical outcome data provides Evaxion with a compelling AI-Immunology™ derived investigational vaccine candidate.
Evaxion Biotech A/S has expanded its collaboration with MSD through an option and license agreement for two preclinical vaccine candidates, EVX-B2 and EVX-B3. The deal includes:
- An upfront payment of $3.2 million
- Up to $10 million in 2025 if MSD exercises its option
- Potential milestone payments of up to $592 million per product
- Royalties on net sales
EVX-B2 targets Gonorrhea, while EVX-B3 targets an undisclosed infectious agent. This agreement validates Evaxion's AI-Immunology™ platform and aligns with their strategy of leveraging external collaborations. Evaxion will host a conference call on September 27, 2024, to discuss the agreement and recent company milestones.
Evaxion Biotech A/S (NASDAQ: EVAX) has launched an enhanced version of its AI-Immunology™ platform, featuring an updated EDEN™ AI prediction model. The new version 5.0 includes:
- A novel toxin antigen predictor
- An expanded training dataset
- Advanced protein feature prediction
These improvements are expected to accelerate vaccine development and strengthen Evaxion's position in AI-driven immunology. The platform can now deliver a new target within 24 hours, compared to years using traditional methods. The enhanced EDEN™ model's performance will be presented at the European Conference on Computational Biology in Turku, Finland.
Evaxion Biotech A/S (NASDAQ: EVAX) reports promising one-year data from its phase 2 trial of EVX-01, an AI-designed personalized cancer vaccine for advanced melanoma. Key findings include:
- 69% Overall Response Rate (11 out of 16 patients)
- Tumor reduction in 15 out of 16 patients
- 79% of vaccine targets triggered immune responses
- Positive correlation between AI-Immunology™ platform predictions and immune responses (p=0.00013)
The trial combines EVX-01 with MSD's KEYTRUDA® (pembrolizumab). These results validate Evaxion's AI-Immunology™ platform and position the company as a leader in AI immunology. With the global melanoma treatment market projected to reach $7.4 billion by 2029, EVX-01 shows significant commercial potential.